This publication has been discontinued on June 28, 2011.
Abstract
Summary
GlobalData, the industry analysis specialist’s new report,
“Attention Deficit Hyperactivity Disorder - Drug Pipeline Analysis
and Market Forecasts to 2015” is an essential source of information and
analysis on the global ADHD market. The report identifies the key trends
shaping and driving the dynamism in the global ADHD market. The report also
provides insight on the prevalent competitive landscape and the emerging
players expected to bring significant shift in the market positioning of the
existing market leaders. Most importantly, the report provides valuable
insight on the pipeline products within the global ADHD sector.
This
report is built using data and information sourced from proprietary databases,
primary and secondary research and in house analysis by GlobalData’s
team of industry experts.
Scope
The scope of the report includes:
- Annualized global ADHD market
revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-
Geographies covered in this report include the US, the UK, Italy, Spain,
Germany, France, and Japan.
- Pipeline analysis data providing a split
across different phases, mechanism of action being developed and emerging
trends. Key classes of mechanism of action include triple reuptake inhibitors,
GABA receptor modulators, acetylcholine receptor agonists, AMPA receptor
modulators, serotonin receptor targettors, selective histamine antagonists,
norepinephrine reuptake inhibitors and alpha-2 adrenergic agonists
-
Analysis of the current and future market competition in the global ADHD
market. Each trend is independently researched to provide qualitative analysis
of what the implications on sectors are, and how are companies responding to
these trends.
- Insightful review of the future market players, key
industry drivers, restraints and challenges which are likely to impact the
ADHD therapeutics market in the long run. Key future market players covered
are Addrenex, Abbott Laboratories, Psychogenics, AstraZeneca and Cortex.
- Key topics covered include strategic competitor assessment, market
characterization, unmet needs and implications for future market associated
with ADHD.
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through review of pipeline products
and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global ADHD market.
- Drive revenues by
understanding key trends, innovative products and technologies, market
segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage.
-
Organize your sales and marketing efforts by identifying the market categories
and segments that present maximum opportunities for consolidations,
investments and strategic partnerships.
- What’s the next big thing
in the global ADHD market landscape? - Identify, understand and
capitalize.
Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2
Attention Deficit Hyperactivity Disorder Market: Market Characterization
2.1 Overview
2.2 Attention Deficit Hyperactivity Disorder Market Size
2.3 Attention Deficit Hyperactivity Disorder Market Forecast and CAGR
2.4
Drivers and Barriers for Attention Deficit Hyperactivity Disorder Market
2.4.1 Drivers for Attention Deficit Hyperactivity Disorder Market
2.4.2
Barriers for Attention Deficit Hyperactivity Disorder Market
2.5
Opportunity and Unmet Need
2.6 Key Takeaway
3 Attention-Deficit
Hyperactivity Disorder Market: Competitive Assessment
3.1 Overview
3.2
Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed
Products in ADHD Market
3.3.1 Daytrana (methylphenidate)
3.3.2 Vyvanse
(lisdexamfetamine dimesylate, NRP-104, S-489)
3.3.3 Strattera (atomoxetine
Hcl)
3.3.4 Intuniv (guanfacine hydrochloride, SPD 503, GXR)
3.3.5
Concerta (methylphenidate Hcl)
3.4 Key Takeaway
4 Attention Deficit
Hyperactivity Disorder Market: Pipeline Assessment
4.1 Overview
4.2
Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical
Framework
4.3 Attention-Deficit Hyperactivity Disorder Therapeutics
- Promising Drugs under Clinical Development
4.4 Molecule Profile
for Promising Drugs under Clinical Development
4.4.1 Clonicel
4.4.2
ABT-089 (Pozanicline)
4.4.3 ABT-894 (Sofinicline)
4.4.4
Eltoprazine
4.4.5 AZD3480 (TC-1734) (Isopronicline)
4.5 Attention
Deficit Hyperactivity Disorder Therapeutics Market - Clinical Pipeline
by Mechanism of Action
4.6 Attention Deficit Hyperactivity Disorder
Pipeline - Pipeline by Clinical Phases of Development
4.6.1
Attention Deficit Hyperactivity Disorder Therapeutics - Phase III
Clinical Pipeline
4.6.2 Attention Deficit Hyperactivity Disorder
Therapeutics - Phase II Clinical Pipeline
4.6.3 Attention Deficit
Hyperactivity Disorder Therapeutics - Phase I Clinical Pipeline
4.6.4 Attention Deficit Hyperactivity Disorder Therapeutics -
Preclinical Pipeline
4.6.5 Attention Deficit Hyperactivity Disorder
Therapeutics - Discovery Pipeline
4.7 Discontinued / Suspended Drugs
for Attention Deficit Hyperactivity Disorder
4.8 Key Takeaway
5
Attention-Deficit Hyperactivity Disorder Market: Implications for Future
Market Competition
6 Attention Deficit Hyperactivity Disorder Market:
Future Players in ADHD Market
6.1 Introduction
6.2 Addrenex
Pharmaceuticals
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Attention
Deficit Hyperactivity Disorder Portfolio
6.3 Abbott Laboratories
6.3.1
Overview
6.3.2 CNS Portfolio
6.3.3 Attention Deficit Hyperactivity
Disorder Product Portfolio
6.4 Psychogenics Inc
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Attention Deficit Hyperactivity Disorder Product
Portfolio
6.5 Cortex Pharmaceuticals
6.5.1 Overview
6.5.2 CNS
Portfolio
6.5.3 Attention Deficit Hyperactivity Disorder Product
Portfolio
6.6 AstraZeneca
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Attention Deficit Hyperactivity Disorder Product Portfolio
7
Attention Deficit Hyperactivity Disorder Market: Appendix
7.1
Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1
Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary
Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5
Disclaimer
7.6 Sources
Table 1: Global ADHD
Therapeutics Market, Revenue Forecasts, 2000-2007
Table 2: Global ADHD
Therapeutics Market, Revenue Forecasts, 2008-15
Table 3: Major marketed
products comparison in ADHD Market, 2009
Table 4: Attention-Deficit
Hyperactivity Disorder Therapeutics - Most Promising Drugs Under
Clinical Development, 2009
Table 5: Attention Deficit Hyperactivity
Disorder Therapeutics - Phase III Clinical Pipeline, 2009
Table 6:
Attention Deficit Hyperactivity Disorder Therapeutics - Phase II
Clinical Pipeline, 2009
Table 7: Attention Deficit Hyperactivity Disorder
Therapeutics - Phase I Clinical Pipeline, 2009
Table 8: Attention
Deficit Hyperactivity Disorder Therapeutics - Preclinical Clinical
Pipeline, 2009
Table 9: Attention Deficit Hyperactivity Disorder
Therapeutics - Discovery Clinical Pipeline, 2009
Table 10: List of
Discontinued Drugs for Attention Deficit Hyperactivity Disorder, 2009
Table 11: Addrenex Laboratories - Pipeline Products, 2009
Table 12: Abbott
Laboratories- CNS Pipeline Products, 2009
Table 13: Abbott
Laboratories- CNS Pipeline Products, 2009
Table 14:
Psychogenics- CNS Pipeline Products, 2009
Table 15: Cortex
Pharmaceuticals - CNS Pipeline Products, 2009
Table 16: AstraZeneca
- CNS Marketed Products, 2009
Table 17: AstraZeneca - CNS
Pipeline Products, 2009
Figure 1: Global ADHD Market Forecast,
2000-2015
Figure 2: Opportunity and Unmet Need, 2009
Figure 3:
Strategic Competitor Assessment, 2009
Figure 4: Technology Trends Analytic
Framework-ADHD Market, 2009
Figure 5: Technology Trends Analytic Framework
- Description-ADHD Market, 2009
Figure 6: ADHD Therapeutics Market
- Clinical Pipeline by Mechanism Of Action, 2009
Figure 7: Attention
Deficit Hyperactivity Disorder Pipeline by Phase of clinical development,
2009
Figure 8: Strategic Competitor Assessment, 2009
Figure 9: ADHD
Therapeutics Market - Clinical Pipeline by Company, 2009
Figure 10:
GlobalData Methodology
Figure 11: Global Market Forecasting Model
